April 19, 2002
Despite Billions for Discoveries, Pipeline of Drugs Is Far From Full
By ANDREW POLLACK
This should be the golden age for pharmaceutical scientists. The deciphering of the human genome is laying bare the blueprint of human life. Medical research has increased understanding of disease. Robots and computers are turning drug discovery from a mixing of chemicals in a test tube to an industrialized, automated process.
Yet if industrialization normally means higher speed and lower costs, the pharmaceutical industry has been experiencing the opposite a "clear fall in productivity," according to Dr. Frank L. Douglas, the chief scientific officer of Aventis. Instead of narrowing the list of compounds that might be useful in drugs, automation has broadened it greatly increasing the number of formulas tested without yet delivering commensurate growth in safe and effective drugs. The industry's output of new drugs has risen only modestly in the last two decades despite a more than sixfold increase, after adjusting for inflation, in research and development spending, to more than $30 billion annually. In the last few years, the output has actually declined.
[Full text: http://www.nytimes.com/2002/04/19/business/19DRUG.html?pagewanted=print]
Carl
_________________________________________________________________ Chat with friends online, try MSN Messenger: http://messenger.msn.com